Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma

Blood Cancer Journal

Volumn 3, Issue 5, 2013, Pages

  Reis Sobreiro, M ^a   Roue, G ^b   Moros, A ^b   Gajate, C ^a   De La Iglesia Vicente, J ^a   Colomer, D ^b   Mollinedo, F ^a  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Akt phosphorylation; Apoptosis; Lipid rafts; Mantle cell lymphoma; PI3K Akt signaling; Synthetic antitumor lipids

Indexed keywords

EDELFOSINE; FAS LIGAND; LIPOCORTIN 5; PERIFOSINE; PERVANADATE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; WORTMANNIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CONTACT; CELL MEMBRANE; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA DEGRADATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LIPID RAFT; MALE; MANTLE CELL LYMPHOMA; MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WEIGHT REDUCTION;

EID: 84878308394     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2013.15     Document Type: Article

References (60)

1. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7: 750-762.
2. Perez-Galan P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011; 117: 26-38.
3. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27: 511-518.
4. Dal Col J, Zancai P, Terrin L, Guidoboni M, Ponzoni M, Pavan A et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 2008; 111: 5142-5151.
5. Rudelius M, Pittaluga S, Nishizuka S, Pham TH, Fend F, Jaffe ES et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006; 108: 1668-1676.
6. Crowell JA, Steele VE, Fay Jr. Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 2007; 6: 2139-2148.
7. Brazil DP, Hemmings BA. Ten years of protein kinase B signalling: a hard Akt to follow. Trends Biochem Sci 2001; 26: 657-664.
8. Franke TF. PI3K/Akt: getting it right matters. Oncogene 2008; 27: 6473-6488.
9. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J 2008; 415: 333-344.
10. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
11. Gao X, Zhang J. Spatiotemporal analysis of differential Akt regulation in plasma membrane microdomains. Mol Biol Cell 2008; 19: 4366-4373.
12. Gao X, Zhang J. Akt signaling dynamics in plasma membrane microdomains visualized by FRET-based reporters. Commun Integr Biol 2009; 2: 32-34.
13. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000; 1: 31-39.
14. Gajate C, Del Canto-Janez E, Acuna AU, Amat-Guerri F, Geijo E, Santos-Beneit AM et al. Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med 2004; 200: 353-365.
15. Gajate C, Mollinedo F. Cytoskeleton-mediated death receptor and ligand concentration in lipid rafts forms apoptosis-promoting clusters in cancer chemotherapy. J Biol Chem 2005; 280: 11641-11647.
16. Reis-Sobreiro M, Gajate C, Mollinedo F. Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions. Oncogene 2009; 28: 3221-3234.
17. Mollinedo F, Gajate C. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist Updat 2006; 9: 51-73.
18. Gajate C, Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 2007; 109: 711-719.
19. Gajate C, Gonzalez-Camacho F, Mollinedo F. Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS One 2009; 4: e5044.
20. Mollinedo F, Gajate C. Lipid rafts, death receptors and CASMERs: new insights for cancer therapy. Future Oncol 2010; 6: 491-494.
21. Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, Campanero MA et al. Lipid raft-targeted therapy in multiple myeloma. Oncogene 2010; 29: 3748-3757.
22. Freeman MR, Di Vizio D, Solomon KR. The rafts of the Medusa: cholesterol targeting in cancer therapy. Oncogene 2010; 29: 3745-3747.
23. Mollinedo F, Gajate C. Lipid rafts and clusters of apoptotic signaling moleculeenriched rafts in cancer therapy. Future Oncol 2010; 6: 811-821.
24. Adam RM, Mukhopadhyay NK, Kim J, Di Vizio D, Cinar B, Boucher K et al. Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res 2007; 67: 6238-6246.
25. Mollinedo F, Fernandez-Luna JL, Gajate C, Martin-Martin B, Benito A, Martinez-Dalmau R et al. Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-XL. Cancer Res 1997; 57: 1320-1328.
26. Gajate C, Fonteriz RI, Cabaner C, Alvarez-Noves G, Alvarez-Rodriguez Y, Modolell M et al. Intracellular triggering of Fas, independently of FasL, as a new mechanism of antitumor ether lipid-induced apoptosis. Int J Cancer 2000; 85: 674-682.
27. Gajate C, Mollinedo F. Biological activities, mechanisms of action and biomedical prospect of the antitumor ether phospholipid ET-18-OCH3 (edelfosine), a proapoptotic agent in tumor cells. Curr Drug Metab 2002; 3: 491-525.
28. Mollinedo F, Gajate C, Martin-Santamaria S, Gago F. ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor. Curr Med Chem 2004; 11: 3163-3184.
29. Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, de Frias M et al. In vitro and in vivo selective antitumor activity of edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res 2010; 16: 2046-2054.
30. van der Luit AH, Budde M, Ruurs P, Verheij M, van Blitterswijk WJ. Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis. J Biol Chem 2002; 277: 39541-39547.
31. Gajate C, Mollinedo F. The antitumor ether lipid ET-18-OCH3 induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 2001; 98: 3860-3863.
32. Beneteau M, Pizon M, Chaigne-Delalande B, Daburon S, Moreau P, De Giorgi F et al. Localization of Fas/CD95 into the lipid rafts on down-modulation of the phosphatidylinositol 3-kinase signaling pathway. Mol Cancer Res 2008; 6: 604-613.
33. Berggren MI, Gallegos A, Dressler LA, Modest EJ, Powis G. Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues. Cancer Res 1993; 53: 4297-4302.
34. Ruiter GA, Zerp SF, Bartelink H, Van Blitterswijk WJ, Verheij M. Anti-cancer alkyllysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 2003; 14: 167-173.
35. Ausili A, Torrecillas A, Aranda FJ, Mollinedo F, Gajate C, Corbalan-Garcia S et al. Edelfosine is incorporated into rafts and alters their organization. J Phys Chem B 2008; 112: 11643-11654.
36. Busto JV, del Canto-Jan? ez E, Gon? i FM, Mollinedo F, Alonso A. Combination of the anti-tumour cell ether lipid edelfosine with sterols abolishes haemolytic side effects of the drug. J Chem Biol 2008; 1: 89-94.
37. O'Shea JJ, McVicar DW, Bailey TL, Burns C, Smyth MJ. Activation of human peripheral blood T lymphocytes by pharmacological induction of protein-tyrosine phosphorylation. Proc Natl Acad Sci USA 1992; 89: 10306-10310.
38. Garrido SM, Appelbaum FR, Willman CL, Banker DE. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 2001; 29: 448-457.
39. Gajate C, Santos-Beneit AM, Macho A, Lazaro M, Hernandez-De Rojas A, Modolell M et al. Involvement of mitochondria and caspase-3 in ET-18-OCH3-induced apoptosis of human leukemic cells. Int J Cancer 2000; 86: 208-218.
40. Gajate C, Santos-Beneit A, Modolell M, Mollinedo F. Involvement of c-Jun NH2-terminal kinase activation and c-Jun in the induction of apoptosis by the ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. Mol Pharmacol 1998; 53: 602-612.
41. Obata T, Yaffe MB, Leparc GG, Piro ET, Maegawa H, Kashiwagi A et al. Peptide and protein library screening defines optimal substrate motifs for AKT/PKB. J Biol Chem 2000; 275: 36108-36115.
42. Wang M, Atayar C, Rosati S, Bosga-Bouwer A, Kluin P, Visser L. JNK is constitutively active in mantle cell lymphoma: cell cycle deregulation and polyploidy by JNK inhibitor SP600125. J Pathol 2009; 218: 95-103.
43. Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011; 30: 2547-2557.
44. Castillo SS, Brognard J, Petukhov PA, Zhang C, Tsurutani J, Granville CA et al. Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res 2004; 64: 2782-2792.
45. Kumar CC, Madison VAKT. crystal structure and AKT-specific inhibitors. Oncogene 2005; 24: 7493-7501.
46. Andersen NS, Larsen JK, Christiansen J, Pedersen LB, Christophersen NS, Geisler CH et al. Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. Blood 2000; 96: 2219-2225.
47. Conus NM, Hannan KM, Cristiano BE, Hemmings BA, Pearson RB. Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase. J Biol Chem 2002; 277: 38021-38028.
48. Mollinedo F, Gajate C, Morales AI, del Canto-Janez E, Justies N, Collia F et al. Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis. J Pharmacol Exp Ther 2009; 329: 439-449.
49. Busto JV, Sot J, Goni FM, Mollinedo F, Alonso A. Surface-active properties of the antitumour ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3- phosphocholine (edelfosine). Biochim Biophys Acta 2007; 1768: 1855-1860.
50. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282: 1318-1321.
51. Gajate C, Gonzalez-Camacho F, Mollinedo F. Lipid raft connection between extrinsic and intrinsic apoptotic pathways. Biochem Biophys Res Commun 2009; 380: 780-784.
52. Mollinedo F, Fernandez M, Hornillos V, Delgado J, Amat-Guerri F, Acuna AU et al. Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria. Cell Death Dis 2011; 2: e158.
53. Plumas J, Jacob MC, Chaperot L, Molens JP, Sotto JJ, Bensa JC. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood 1998; 91: 2875-2885.
54. Clodi K, Snell V, Zhao S, Cabanillas F, Andreeff M, Younes A. Unbalanced expression of Fas and CD40 in mantle cell lymphoma. Br J Haematol 1998; 103: 217-219.
55. Mollinedo F, Gajate C. FasL-independent activation of Fas. In: Wajant H (ed). Fas Signaling. Landes Bioscience and Springer Science: Georgetown, TX, USA, 2006, pp 13-27.
56. Vilimek D, Duronio V. Cytokine-stimulated phosphorylation of GSK-3 is primarily dependent upon PKCs, not PKB. Biochem Cell Biol 2006; 84: 20-29.
57. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2003; 2: 1093-1103.
58. Hope HR, Pike LJ. Phosphoinositides and phosphoinositide-utilizing enzymes in detergent-insoluble lipid domains. Mol Biol Cell 1996; 7: 843-851.
59. Hill MM, Feng J, Hemmings BA. Identification of a plasma membrane raft-associated PKB Ser473 kinase activity that is distinct from ILK and PDK1. Curr Biol 2002; 12: 1251-1255.
60. Alderliesten MC, Klarenbeek JB, van der Luit AH, van Lummel M, Jones DR, Zerp S et al. Phosphoinositide phosphatase SHIP-1 regulates apoptosis induced by edelfosine, Fas ligation and DNA damage in mouse lymphoma cells. Biochem J 2011; 440: 127-135.